Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Down Syndrome 1Burkitt Lymphoma 1

Interventions

pembrolizumab 60Carboplatin 60Paclitaxel 51Magnetic Resonance Spectroscopy 42Specimen Handling 41Cisplatin 41Gemcitabine 34Bevacizumab 31Docetaxel 30Leucovorin 27Doxorubicin 27Fluorouracil 26Dexamethasone 25Cyclophosphamide 25Pemetrexed 23Radiotherapy 22Radiation 22Oxaliplatin 22Etoposide 21durvalumab 20Nivolumab 20Vincristine 19Taxes 19Rituximab 19Irinotecan 19Prednisone 18Letrozole 18Capecitabine 17Lenalidomide 16Immunoglobulin G 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × asparaginase erwinia chrysanthemi recombinant × 30 days × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡